Literature DB >> 7953639

Hyperthermia complicates middle cerebral artery occlusion induced by an intraluminal filament.

Q Zhao1, H Memezawa, M L Smith, B K Siesjö.   

Abstract

The present experiments were designed to study under what circumstances middle cerebral artery (MCA) occlusion by an intraluminal filament technique leads to hyperthermia and what the mechanisms are. We found that permanent MCA occlusion by this technique lead to a rise in body (core) temperature to 39.0-39.5 degrees C during the first 2-4 h, and to sustained hyperthermia thereafter (38.5-39.0 degrees C). After 2 h of transient MCA occlusion hyperthermia could only be avoided if anesthesia (with control of temperature) was maintained for 2 h of ischemia and 1 h of recirculation or, in unanesthetized animals, if external cooling was maintained for 2 h of ischemia and 2 h of recirculation. Control of temperature only during ischemia did not prevent a postischemic rise in temperature. One hour of MCA occlusion had less effect on body temperature. Results are presented which suggest that the hyperthermia observed is due to an interference, by the intraluminal filament, of circulation to hypothalamic centers regulating body temperature. It is speculated that the hyperthermia induced may blunt or obliterate the effect of drugs, normally considered to ameliorate brain damage due to focal ischemia.

Entities:  

Mesh:

Year:  1994        PMID: 7953639     DOI: 10.1016/0006-8993(94)91071-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  26 in total

Review 1.  Epileptogenesis after experimental focal cerebral ischemia.

Authors:  Heli Karhunen; Jukka Jolkkonen; Juhani Sivenius; Asla Pitkänen
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

Review 2.  Experimental approaches to study functional recovery following cerebral ischemia.

Authors:  Anu Lipsanen; Jukka Jolkkonen
Journal:  Cell Mol Life Sci       Date:  2011-05-29       Impact factor: 9.261

Review 3.  Postischemic hypothermia. A critical appraisal with implications for clinical treatment.

Authors:  F Colbourne; G Sutherland; D Corbett
Journal:  Mol Neurobiol       Date:  1997-06       Impact factor: 5.590

4.  Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat.

Authors:  Nicholas J Mulcahy; Jerard Ross; Nancy J Rothwell; Sarah A Loddick
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

5.  Rodent models of focal cerebral ischemia: procedural pitfalls and translational problems.

Authors:  Stefan Braeuninger; Christoph Kleinschnitz
Journal:  Exp Transl Stroke Med       Date:  2009-11-25

6.  Neuronal precursor cell proliferation in the hippocampus after transient cerebral ischemia: a comparative study of two rat strains using stereological tools.

Authors:  Jesper Kelsen; Marianne H Larsen; Jens Christian Sørensen; Arne Møller; Jørgen Frøkiaer; Søren Nielsen; Jens R Nyengaard; Jens D Mikkelsen; Lars Christian B Rønn
Journal:  Exp Transl Stroke Med       Date:  2010-04-06

7.  Animal models of focal brain ischemia.

Authors:  Kenneth M Sicard; Marc Fisher
Journal:  Exp Transl Stroke Med       Date:  2009-11-13

8.  Expression and function of striatal enriched protein tyrosine phosphatase is profoundly altered in cerebral ischemia.

Authors:  Steven P Braithwaite; Jian Xu; John Leung; Roman Urfer; Karoly Nikolich; Donna Oksenberg; Paul J Lombroso; Mehrdad Shamloo
Journal:  Eur J Neurosci       Date:  2008-05       Impact factor: 3.386

9.  N-tert-butyl-alpha-phenylnitrone improves recovery of brain energy state in rats following transient focal ischemia.

Authors:  J Folbergrová; Q Zhao; K Katsura; B K Siesjö
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

10.  Effects of progesterone administration on infarct volume and functional deficits following permanent focal cerebral ischemia in rats.

Authors:  Tauheed Ishrat; Iqbal Sayeed; Fahim Atif; Donald G Stein
Journal:  Brain Res       Date:  2008-12-29       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.